CariGenetics Saint Lucia launched to advance precision medicine in OECS
Tech Analytica has officially rebranded as CariGenetics Saint Lucia, representing a key step in advancing Caribbean-led genomics, precision medicine, and health innovation in Saint Lucia and the wider OECS region. CariGenetics, headquartered in Bermuda, is a genomics organisation dedicated to improving health outcomes in the Caribbean through research, education, and precision medicine. The company addresses […] The article CariGenetics Saint Lucia launched to advance precision medicine in OECS is from St. Lucia Times.
Black News 
Tech Analytica has officially rebranded as CariGenetics Saint Lucia, representing a key step in advancing Caribbean-led genomics, precision medicine, and health innovation in Saint Lucia and the wider OECS region.
CariGenetics, headquartered in Bermuda, is a genomics organisation dedicated to improving health outcomes in the Caribbean through research, education, and precision medicine. The company addresses global health data gaps by generating genomic data from historically underrepresented Caribbean populations.
The rebranding follows 18 months of collaboration between GenTech Analytica and CariGenetics, during which both teams expanded access to genetic education, testing, research, and regional health engagement. This partnership led to initiatives such as Saint Lucia’s first prostate cancer genetic study and the introduction of genetic testing services to improve access to personalised health insights.
This change unifies Caribbean genetic research under one brand, strengthening regional identity. The teams have presented key genomic and health statistics to the OECS, demonstrating how genetic insights can inform targeted approaches to cancer, non-communicable diseases, medication safety and long-term public health planning. They also proposed ways to integrate genomics into regional health systems responsibly and in ways relevant to local needs.
This expansion enhances CariGenetics’ capacity to support governments, healthcare providers, research partners, and communities with genomic education and ethical research participation. It will provide practical tools to inform prevention, treatment and public health decision-making, supported by a coordinated approach and a strong local team in the OECS.
Dr Carika Weldon, founder and CEO of CariGenetics, said this move reflects CariGenetics’ commitment to building scientific capacity across the Caribbean while ensuring that local communities remain at the centre of genomic innovation.
“This is about more than business growth. It is about building the infrastructure, trust, and partnerships needed to ensure Caribbean people are represented in the future of precision medicine with excellent local talent,” said Dr Weldon. “Through CariGenetics Saint Lucia, we are strengthening our ability to work alongside local and regional partners to advance research, improve education and support more personalised approaches to healthcare for our communities.”
For GenTech Analytica, this marks the next chapter in a journey that began two years ago with a clear vision: to ensure the Caribbean is included in the future of genetics and precision medicine. Since then, GenTech Analytica has evolved from an early-stage idea into a platform for scientific communication, regional engagement, and health innovation.
“GenTech Analytica started with the belief that the Caribbean should have a voice in the future of genetics and precision medicine,” said Devy Frederick, founder of GenTech Analytica and newly appointed CEO of CariGenetics Saint Lucia. “To see that vision now become CariGenetics Saint Lucia after two years is a proud moment. I hope this also encourages other young Caribbean entrepreneurs to take their ideas seriously, build partnerships, and create solutions that can contribute meaningfully to the development of our region.”
Looking ahead, CariGenetics Saint Lucia will focus on advancing Caribbean-led research, expanding access to genetic testing, supporting clinical and public health decision-making, and building partnerships to ensure Caribbean populations are represented in genomic science. Key priorities include cancer genomics, wellness genetic testing, pharmacogenetics, polygenic risk scores, and the development of responsible frameworks for genomic data use.
These areas are central to the future of precision medicine. For example, pharmacogenetics identifies how a person’s genes affect their response to medications, while polygenic risk scores offer insight into inherited risk patterns that can support earlier prevention, screening and public health planning.
This transition is more than a business milestone. It demonstrates a shared commitment to ensuring Caribbean people are not only participants in global genomics but also leaders in shaping the development and delivery of precision medicine across the region.
As the Caribbean faces a high burden of non-communicable diseases, CariGenetics aims to support earlier identification, prevention, and more personalised healthcare.
The article CariGenetics Saint Lucia launched to advance precision medicine in OECS is from St. Lucia Times.
